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ABSTRACT
For optimal compatibility with biopharmaceutical
manufacturing and gene therapy, heterologous
transgene control systems must be responsive to
side-effect-free physiologic inducer molecules.
The arginine-inducible interaction of the ArgR
repressor and the ArgR-specific ARG box, which
synchronize arginine import and synthesis in
the intracellular human pathogen Chlamydia
pneumoniae, was engineered for arginine-regulated
transgene (ART) expression in mammalian cells.
A synthetic arginine-responsive transactivator
(ARG), consisting of ArgR fused to the Herpes
simplex VP16 transactivation domain, reversibly
adjusted transgene transcription of chimeric ARG
box-containing mammalian minimal promoters
(PART) in an arginine-inducible manner. Arginine-
controlled transgene expression showed rapid
induction kinetics in a variety of mammalian cell
lines and was adjustable and reversible at concen-
trations which were compatible with host cell
physiology. ART variants containing different trans-
activation domains, variable spacing between
ARG box and minimal promoter and several
tandem ARG boxes showed modified regulation
performance tailored for specific expression sce-
narios and cell types. Mice implanted with micro-
encapsulated cells engineered for ART-inducible
expression of the human placental secreted alkaline
phosphatase (SEAP) exhibited adjustable serum
phosphatase levels after treatment with different
arginine doses. Using a physiologic inducer, such as
the amino acid L-arginine, to control heterologous
transgenes in a seamless manner which is devoid of
noticeable metabolic interference will foster novel
opportunities for precise expression dosing in future
gene therapy scenarios as well as the manufactur-
ing of difficult-to-produce protein pharmaceuticals.
INTRODUCTION
Conditional transcription control systems which ﬁne-tune
heterologous transgene expression in mammalian cells
are fundamental for gene-function analysis (1,2), drug
discovery (3,4), expression dosing in gene therapy (5),
design of synthetic gene networks and for manufacturing
of diﬃcult-to-produce protein pharmaceuticals (6,7).
Currently available mammalian transgene control systems
capitalize on a generic design consisting of a synthetic
transactivator (transrepressor), typically derived from
a prokaryotic response regulator fused to a mammalian
transactivation (transrepression) domain and a chimeric
promoter assembled by cloning transactivator-speciﬁc
operator sites adjacent to a minimal (constitutive)
eukaryotic promoter (8–10). Binding of an inducer
molecule modulates the aﬃnity of the transactivator
(transrepressor) for the cognate promoter and either
induces (ON-type systems, (11–14)) or represses (OFF-
type systems, (14,15)) transcription of linked transgenes.
Trigger molecules and parameters include antibiotics
(10,14,16), hormones and hormone analogs (17–19),
quorum sensing substances (12,20,21), temperature (22),
the redox poise (20), immunosuppressive and antidiabetic
drugs (23,24), gaseous acetaldehyde (11) and biotin (25).
Although most of these established gene regulation
systems show excellent regulation performance in vitro
as well as in animals, the inducer molecules are often
incompatible with gene therapy and biopharmaceutical
manufacturing scenarios because of their side-eﬀects,
which are well documented for hormones and some of
their analogs (26,27), antibiotics (28–30) and immunosup-
pressive drugs (31,32). While the biopharmaceutical
manufacturing industry strives to develop gene regulation
systems controlled by FDA-approved media components
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ing procedures (33), the gene therapy community dreams
of capturing pathologic signals which can be converted
into a well-tuned therapeutic intervention. The common
interest is exploiting physiologic signal molecules for
titration of heterologous product gene expression and
prevent interference between endogenous and synthetic
regulatory circuits.
As an obligate intracellular pathogen infecting the
respiratory tracts and causing pneumonia and athero-
sclerotic heart disease (34–37), Chlamydia pneumoniae has
evolved to capture physiologic signals and synchronize
its metabolism with the host cell (38). For example, the
coordination of arginine biosynthesis and catabolism with
availability of this amino acid in host cells is managed
by ArgR, a master regulatory molecule acting as an
arginine-dependent apo-repressor that speciﬁcally binds to
arginine-responsive transactivator (ARG) box operators
anzd represses the glnPQ operon which encodes a puta-
tive arginine transport system in an arginine-responsive
manner (39,40). ArgR, which is highly conserved in
bacterial systems, can function both as transcriptional
repressor or activator (41,42). In Escherichia coli, ArgR
negatively regulates the expression of the arginine
biosynthetic genes in response to intracellular L-arginine
levels (43). When acting as a repressor, ArgR requires
allosteric activation by L-arginine to bind to an 18-bp
palindromic operator sequence known as the ARG
box (39,43–45). While the N-terminal half of ArgR
contains a winged helix-turn-helix family DNA binding
domain, the C-terminal half is responsible for arginine
binding.
We have engineered ArgR and the ARG box of
C. pneumoniae for L-arginine-regulated transgene (ART)
regulation system in mammalian cells. As an ON-type
system by default, ART remained silent at minimal
endogenous L-arginine concentrations and was adjustably
induced by increasing L-arginine levels. Using a proteo-
genic amino acid to control heterologous transgene in
mammalian cells grown in monolayer cultures or in mice
should foster new opportunities in gene therapy and
biopharmaceutical manufacturing.
MATERIALS AND METHODS
Plasmid construction
All plasmids and oligonucleotides constructed and used in
this study are listed in Table 1. Details on vector design
are also provided in Table 1.
Cellculture, transfection and construction ofstable cell lines
Wild-type Chinese hamster ovary cells (CHO-K1, ATCC:
CCL-61) and its derivatives [e.g. CHO-ET1-SEAP1; (10)]
were cultivated in L-arginine-free ChoMaster HTS (Cell
Culture Technologies, Gravesano, Switzerland) supple-
mented with 10mg/l L-arginine, 5% (v/v) fetal calf serum
(FCS, PAN Biotech GmbH, Aidenbach, Germany, Cat.
No. 3302, Lot No. P251110) and 1% (v/v) penicillin/
streptomycin solution (Sigma, St Louis, MO, USA, Cat.
No. P4458). Human ﬁbrosarcoma cells (HT-1080, ATCC,
CCL-121), African green monkey kidney cells (COS-7,
ATCC CRL-1651) and human embryonic kidney cells,
transgenic for the simian virus 40 (SV40) large T antigen
[HEK293-T, (46)], were cultivated in L-arginine-free
Hektor G (Cell Culture Technologies, Gravesano,
Switzerland) supplemented with 10mg/l L-arginine, 10%
(v/v) FCS and 1% (v/v) penicillin/streptomycin solution.
Mouse ﬁbroblasts (NIH/3T3, ATCC: CRL-1658) were
cultured in Dulbecco’s modiﬁed Eagle’s medium (DMEM,
Invitrogen, Basel, Switzerland, Cat. No. 52100-39) sup-
plemented with 10% FCS and 1% (v/v) penicillin/
streptomycin solution. All cell types were cultivated at
378C in a humidiﬁed atmosphere containing 5% CO2.
For DNA transfection, 1.2mg DNA (for co-transfection
an equal amount of each plasmid) was transfected into
55000 cells pre-cultivated for 24h in a well of a 24-well
plate. For transfection of CHO-K1, the plasmid DNA was
diluted into a total volume of 25ml 0.5M CaCl2 solution,
mixed with 25mlP O
3 
4 solution (100mM HEPES, 280mM
NaCl, 1.5mM Na2HPO4, pH 7.1) and incubated for
15min at room temperature. The DNA–calcium phos-
phate complex was added, and centrifuged onto the cells
(5min at 1200g) to increase transfection eﬃciency. After
incubation for 2h, the cells were exposed to a glycerol
shock for 30s (L-arginine-free ChoMaster HTS medium
supplemented with 15% glycerol). After a single washing
with phosphate-buﬀered saline (PBS, Dulbecco’s phos-
phate-buﬀered saline, Invitrogen, Basel, Switzerland, Cat.
No. 21600-0069), the cells were cultivated in ChoMaster
HTS supplemented with diﬀerent L-arginine concentra-
tions. For transfection of COS-7, HEK293-T, the
standard calcium phosphate-based transfection protocol
was used (21) and transfected populations were cultivated
in Hektor G supplemented with diﬀerent L-arginine
concentrations. HT-1080 and NIH/3T3 were transfected
with Fugene
TM 6 (Roche Diagnostics AG, Basel,
Switzerland, Cat. No. 11814443001) following the suppli-
er’s protocol and cultivated in Hektor G and DMEM,
respectively. Production of the reporter protein was
assessed in the culture supernatants 60h after transfection,
unless indicated otherwise.
CHO-ARG2-SEAP, transgenic for L-arginine-
controlled SEAP expression, was constructed by sequen-
tial co-transfection and clonal selection of (i) pSH91 and
pPur (Clontech, Cat. No. 6156-1) (CHO-ARG2) and
(ii) pSH93 and pSV2neo (Clontech, Cat. No. 6172-1)
(CHO-ARG2-SEAP). To assess the dose–response
characteristics of ART-regulated gene expression, CHO-
ARG2-SEAP was cultured at 110000 cells/ml for 60h
in L-arginine-free ChoMaster HTS supplemented
with L-arginine ranging from 10mg/l to 10000mg/l.
Reversibility of L-arginine-mediated SEAP
production was assessed by cultivating CHO-ARG2-
SEAP (110000 cells/ml) for 1 week while alternating
L-arginine concentrations from 10 to 1000mg/l every 48h.
Western blot analysis
Sixty hours after transfection of 350000 HEK-293T
cells with the vector encoding ARG2 (pSH91,
PSV40-ARG2-pA), the cell lysate was heat denaturated in
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Plasmid Description and cloning strategy Reference or source
pRevTRE Oncoretroviral expression vector containing a tetracycline-responsive expression unit Clontech, Palo Alto,
CA, USA
pPur Selection vector conferring puromycin resistance to eukaryotic cells Clontech, Palo Alto,
CA, USA
pSV2neo Selection vector conferring neomycin resistance to eukaryotic cells Clontech, Palo Alto,
CA, USA
pBP10 Vector encoding a PETR5-driven SEAP expression unit (PETR5-SEAP-pA; PETR5,
ETR-2bp-PhCMVmin)
(9)
pBP11 Vector encoding a PETR6-driven SEAP expression unit (PETR6-SEAP-pA; PETR6,
ETR-4bp-PhCMVmin)
(9)
pBP12 Vector encoding a PETR7-driven SEAP expression unit (PETR7-SEAP-pA; PETR7,
ETR-6bp-PhCMVmin)
(9)
pBP13 Vector encoding a PETR8-driven SEAP expression unit (PETR8-SEAP-pA; PETR8,
ETR-8bp-PhCMVmin)
(9)
pBP14 Vector encoding a PETR9-driven SEAP expression unit (PETR9-SEAP-pA; PETR9,
ETR-10bp-PhCMVmin)
(9)
pMF111 Vector encoding a PhCMVmin-driven SEAP expression unit (PhCMVmin-SEAP-pA) (69)
pMT1227 Vector encoding the C. pneumoniae CWL029 ArgR gene (39)
pWW35 Constitutive ET1 expression vector (PSV40-ET1-pA) (10)
pWW42 Constitutive ET2 expression vector (PSV40-ET2-pA) (10)
pWW64 Constitutive ET3 expression vector (PSV40-ET3-pA) (9)
pSH91 Constitutive ARG2 expression vector (PSV40-ARG2-pA) argR was ampliﬁed from pMT1227
using OSH49: 50-gatcgaattcccaccATGA AAAAAAAAGTAAC TATAGATGAGG-30 and
OSH50: 50-cttatggcgcgcggctgtacgc ggaATCCAAGAA AACTTGCAGTA AATTTG-30 (upper
case, annealing sequence; lower case italic, restriction sites), digested with EcoRI/BssHII and
ligated into pWW35 (EcoRI/BssHII).
This work
pSH92 Vector encoding OARG-0bp-PhCMVmin-ET1-pA OARG-0bp-PhCMVmin was ampliﬁed from
pRevTRE using OSH51: 50-gatcgacgtcAGTTTTCTTGGATTAATTGCATAAATATGATTTCAT
TATAAATAAATATGCATAAGAGGTCGGAGTGcctgcaggTCGAGCTCGGTACCCGGGTC-30
and OWW22: 50-gctagaattcCGCGGAGGCTGGATCGG-30 (upper case, annealing sequence;
lower case italic, restriction sites; upper case italic, OARG), digested with AatII/EcoRI and ligated
into pWW35 (AatII/EcoRI).
This work
pSH93 Vector encoding a PART1-driven expression unit (PART1-SEAP-pA; PART1,O ARG-0bp-PhCMVmin)
OARG-0bp-PhCMVmin was excised from pSH92 (SspI/EcoRI) and ligated into pMF111 (SspI/
EcoRI).
This work
pSH105 Vector encoding a PART2-driven expression unit (PART2-SEAP-pA; PART2,O ARG-2bp-PhCMVmin)
2bp-PhCMVmin-SEAP was excised from pBP10 (SbfI/XhoI) and ligated into pSH93 (SbfI/XhoI).
This work
pSH106 Vector encoding a PART3-driven expression unit (PART3-SEAP-pA; PART3,O ARG-4bp-PhCMVmin)
4bp-PhCMVmin-SEAP was excised from pBP11 (SbfI/XhoI) and ligated into pSH93 (SbfI/XhoI).
This work
pSH107 Vector encoding a PART4-driven expression unit (PART4-SEAP-pA; PART4,O ARG-6bp-PhCMVmin)
6bp-PhCMVmin-SEAP was excised from pBP12 (SbfI/XhoI) and ligated into pSH93 (SbfI/XhoI).
This work
pSH108 Vector encoding a PART5-driven expression unit (PART5-SEAP-pA; PART5,O ARG-8bp-PhCMVmin)
8bp-PhCMVmin-SEAP was excised from pBP13 (SbfI/XhoI) and ligated into pSH93 (SbfI/XhoI).
This work
pSH109 Vector encoding a PART6-driven expression unit (PART6-SEAP-pA; PART6,O ARG-10bp-PhCMVmin)
10bp-PhCMVmin-SEAP was excised from pBP14 (SbfI/XhoI) and ligated into pSH93 (SbfI/XhoI).
This work
pSH115 Vector encoding AscI-OARG-MluI-0bp-PhCMVmin-ET1-pA AscI-OARG-MluI-0bp-PhCMVmin was
ampliﬁed from pRevTRE using OSH69: 50-gatcgacgtcggcgcgccAGTTTTCTTGGATTAAT
TGCATAAATATGATTTCATTATAAATAAATATGCATAAGAGGTCGGAGTGacgcgtcctgcagg
TCGAGCTCGGTACCCGGGTC-30 and OWW22: 50-gctagaattcCGCGGAGGCTGGATCGG-
30 (upper case, annealing sequence; lower case italic, restriction sites; upper case italic, OARG),
digested with AatII/EcoRI and ligated into pWW35 (AatII/EcoRI).
This work
pSH117 Vector encoding a PARTm1-driven expression unit (PARTm1-SEAP-pA; PARTm1, AscI-OARG-MluI-
0bp-PhCMVmin) AscI-OARG-MluI-0bp-PhCMVmin was excised from pSH115 (SspI/EcoRI) and
ligated into pSH93 (SspI/EcoRI).
This work
pSH119 Vector encoding a PARTm2-driven expression unit (PARTm2-SEAP-pA; PARTm2, AscI-OARG-7bp-
OARG-MluI-0bp-PhCMVmin) AscI-OARG-MluI-0bp-PhCMVmin-SEAP was excised from pSH117
(AscI/XhoI) and ligated into pSH117 (MluI/XhoI).
This work
pSH120 Constitutive ARG1 expression vector (PSV40-ARG1-pA) The NF-kB-derived transcription
domain (p65) was excised from pWW42 (BssHII/BamHI) and ligated into pSH91 (BssHII/
BamHI).
This work
pSH121 Constitutive ARG3 expression vector (PSV40-ARG3-pA) The E2F4-derived transcription domain
(E2F4) was excised from pWW64 (BssHII/BamHI) and ligated into pSH91 (BssHII/BamHI).
This work
pSH122 Autoregulated vector encoding a PART1-driven expression unit (PART1-SEAP-IRESPV-ARG2-pA)
ARG2 was excised from pSH91 (NotI/XbaI) and ligated into pSH93 (NotI/NheI).
This work
pSH126 Vector encoding a PARTm3-driven expression unit (PARTm3-SEAP-pA; PARTm3, AscI-OARG-
7bp-OARG-7bp-OARG–MluI-0bp-PhCMVmin) AscI-OARG-7bp-OARG–MluI-0bp-PhCMVmin-SEAP
was excised from pSH119 (AscI/XhoI) and ligated into pSH117 (MluI/XhoI).
This work
(Continued)
PAGE 3 OF 13 Nucleic Acids Research, 2007, Vol. 35,No. 20 e1365  SPS-PAGE reducing sample buﬀer (50% glycerol,
250mM Tris, 10% sodium dodecylsulfate, 500mM
dithiothreitol, 0.01% bromophenolblue, pH 6.8) at 858C
for 3min and size-fractionated on a 12% SDS-polyacry-
lamide gel. The gel was transferred to a polyvinylidene
ﬂuoride membrane (Millipore Corporation, Bedford,
USA. Cat. No. IPVH20200) and blocked overnight with
5% low fat milk (Migros, Switzerland) in PBS. The target
protein was detected with a primary monoclonal anti-
VP16 (Santa Cruz Biotechnology Inc., California, Cat.
No. sc-7545, 1:100 dilution in 5% low fat milk in PBS)
and visualized using a secondary HRP-coupled anti-
mouse IgG (Amersham Biosciences UK Limited,
Buckinghamshire, UK, Cat. No. NA931V, 1:1000 dilu-
tion in 5% low fat milk in PBS) and a chemiluminescence-
based assay (GE Healthcare Amersham UK Limited,
Buckinghamshire, UK, Cat. No. RPN2132). Following
the same protocol, tubulin-a was visualized as a loading
control (Ab-2 (DM1A); Neomarkers, California, Cat. No.
MS-581-P1).
Regulating L-arginine and L-arginine analogs
L-arginine stock solution was prepared in water by
adjusting 50g/l L-arginine base (0.287M, AppliChem,
Darmstadt, Germany, Cat. No. A3653,0100) to pH 7.2
with HCl and used at the ﬁnal concentrations indicated.
L-ornithine hydrochloride (Fluka, Buchs, Switzerland,
Cat. No. 75470) and L-citrulline (Fluka, Buchs,
Switzerland, Cat. No. 27510), L-homoarginine hydro-
chloride (Acros Organics, Basel, Switzerland, Cat. No.
169090050) were dissolved in water (0.287M) with pH
adjusted to 7.2 by NaOH. L-arginine methyl ester
dihydrochloride (Fluka, Buchs, Switzerland, Cat. No.
11030), L-arginine ethyl ester dihydrochloride (Sigma-
Aldrich, Steinheim, Germany, Cat. No. A2883), agmatine
sulfate (Sigma-Aldrich, Cat. No. A7127) and L-canava-
nine sulfate (Sigma-Aldrich, Cat. No. C9758) stock
solutions were prepared by adjusting the pH of a
0.144M solution to pH 7.2.
Quantification of reporter gene expression
Production of the human placental secreted
alkaline phosphatase (SEAP) was quantiﬁed using a
p-nitrophenylphosphate-based light absorbance time
course (47,48). Interferon-b quantiﬁcation was determined
using the human Interferon b-speciﬁc ELISA (PBL
Laboratories, NJ, USA, Cat. No. 41400-1) according to
the manufacturer’s protocol.
Determination ofosmolarity
The osmolarity of ChoMaster HTS medium supplemen-
ted with diﬀerent L-arginine concentrations was assessed
with a Vapro according to the manufacturer’s instruc-
tions (Wescor Inc., Logan, UT, USA).
In vivomethods
CHO-K1 cells, engineered for L-arginine-controlled SEAP
expression (CHO-ARG2-SEAP), were encapsulated into
400mm alginate-poly-(L-lysine)-alginate beads (200 cells/
capsule) using the Inotech Encapsulator Research IE-50R
(Inotech Biotechnologies Ltd, Basel, Switzerland) accord-
ing to the manufacturer’s protocol and the following
parameters: 0.2mm nozzle, 20ml syringe at a ﬂow rate of
405 units, nozzle vibration frequency 1024Hz, voltage
for bead dispersion 900V. Seven hundred microliters of
L-arginine-free ChoMaster HTS containing 2 10
6
encapsulated cells (10
4 capsules/mouse) were injected
intraperitoneally into mice (oncins France souche 1,
Charles River Laboratories, France). One hour after
implantation, L-arginine was administered by injection at
doses ranging from 0 to 100mg/kg. L-arginine
was prepared for in vivo administration by diluting the
L-arginine stock solution (see above) with an iso-osmotic
0.9% NaCl solution to obtain the appropriate concentra-
tions. Control mice were implanted with capsules contain-
ing wild-type CHO-K1 cells. Seventy-two hours after
implantation, the mice were sacriﬁced and their blood
collected. For SEAP quantiﬁcation, serum was isolated
using a microtainer SST tube (Beckton Dickinson,
Plymouth, UK) according to the manufacturer’s protocol.
All experiments involving mice were performed according
to the European Community Council directive (86/609/
EEC), approved by the French Ministry of Agriculture
and Fishery (Paris, France) and performed by M.D-E.-B.
at the Institut Universitaire de Technologie, IUTA,
F-69622 Villeurbanne Cedex, France.
Table 1. Continued
Plasmid Description and cloning strategy Reference or source
pSH127 Vector encoding a PARTm4-driven expression unit (PARTm4-SEAP-pA; PARTm4, AscI-OARG-7bp-
OARG-7bp-OARG–7bp-OARG-MluI-0bp-PhCMVmin) AscI-OARG-7bp-OARG–MluI-0bp-PhCMVmin-
SEAP was excised from pSH119 (AscI/XhoI) and ligated into pSH119 (MluI/XhoI).
This work
ArgR, transactivator of the C. pneumoniae CWL029 of the glnPQ operon; ARG1, L-arginine-dependent transactivator (ArgR-p65); ARG2,
L-arginine-dependent transactivator (ArgR-VP16); ARG3, L-arginine-dependent transactivator (ArgR-E2F4); E2F4, transactivation domain of the
human E2F4; ET1, macrolide-dependent transactivator (E-VP16); ET2, macrolide dependent transactivator (E-p65); ET3, macrolide dependent
transactivator (E-E2F4); ETR, operator module speciﬁc for MphR(A); IRESPV, internal ribosome entry site of polioviral origin; NF-kB,
human transcription factor; OARG, ArgR-speciﬁc operator; p65, transactivation domain of NF-kB; pA, SV40-derived polyadenylation site; PART1-6,
L-arginine-responsive promoters containing diﬀerent spacers between OARG and PhCMVmin;P ARTm1-4, L-arginine-responsive promoters containing one
(PARTm1), two (PARTm2), three (PARTm3) or four (PARTm4) operator sequences upstream of PhCMVmin;P hCMV, human cytomegalovirus immediate
early promoter; PETR5-9, macrolide-responsive promoters containing diﬀerent spacers between ETR and PhCMVmin;P hCMVmin, minimal version of
the human cytomegalovirus promoter; PSV40, constitutive simian virus 40 promoter; SEAP, human placental secreted alkaline phosphatase;
VP16, H. simplex virus-derived transactivation domain.
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Determination of the L-arginine concentration range
compatible withhostphysiology and potential L-arginine-
controlled gene expression
Since L-arginine plays a central role in the urea cycle,
the synthesis of nitric oxide and for the synthesis of
cytoplasmic and nuclear proteins (49), it is often the rate-
limiting amino acid in fast-growing organisms (50,51).
In order to prevent L-arginine becoming a physiologic
bottleneck or endogenous L-arginine interfering with
ART-controlled transgene expression in mammalian
cells, we exposed a CHO-K1-derived SEAP-expressing
cell line [CHO-ET1-SEAP1, (10)] to L-arginine concentra-
tions ranging from 0 to 10000mg/l and scored SEAP
levels and cell density after a 60h cultivation period.
A 10mg/l L-arginine was suﬃcient to support robust
wild-type-like cell growth with SEAP production levels
equivalent to control cultivations in standard ChoMaster
HTS medium containing a default L-arginine concen-
tration of 200mg/l (Figure 1). This observation is
quantitatively comparable with physiologic plasma con-
centrations of L-arginine found in mice and humans
[ 17mg/l, (52)]. Between 10mg/l and 2g/l of L-arginine,
SEAP production and cell densities were comparable to
populations cultivated in standard ChoMaster HTS
medium. At L-arginine concentrations above 2g/l the
culture media became hyperosmotic (>310mOsm) which
compromised cell viability and titer (Figure 1). Based on
this data, we selected 10mg/l and 1g/l as low and high
L-arginine concentrations in follow-up experiments.
Design ofa L-arginine-responsive mammalian transcription
control system
Capitalizing on the ArgR repressor of Chlamydia
pneumoniae, which manages arginine metabolism by
binding to speciﬁc operator sequences (OARG) upstream
of the glnPQ operon in a L-arginine-inducible manner, we
have designed a L-arginine-regulated transgene control
system (ART) which ﬁne-tunes transgene transcription in
mammalian cells. ART consists of two components, a
L-arginine-regulated transactivator (ARG1) and an
ARG1-speciﬁc synthetic promoter (PART1): (i) ARG1
was designed by fusing ArgR C-terminally to the human
NF-kB transactivation domain (ARG1, ArgR-p65;
pSH120, PSV40-ARG1-pA) (8,39). (ii) PART1 was
assembled by cloning an ArgR-speciﬁc operator module
harboring two ARG boxes separated by a single base pair
triplet (OARG, AGTTTTCTTGGATTAATTGCATAAA
TATGATTTCATTATAAATAAATATGCATAAGAGGT
CGGAGTG; predicted ARG boxes underlined) 50 of a
minimal version of the human cytomegalovirus immediate
early promoter (PhCMVmin;P ART1,O ARG–PhCMVmin;
pSH93, PART1–SEAP-pA; Figure 2A) (15,39). Upon co-
transfection of pSH120 (PSV40–ARG1-pA) and pSH93
(PART1–SEAP-pA) into CHO-K1, SEAP expression
remained repressed in the presence of 10mg/l and could
be induced by addition of L-arginine up to 1g/l, suggesting
that ARG1 binds and transactivates PART1 in mammalian
cells akin to L-arginine-triggered induction of the glnPQ
operon by ArgR in Chlamydia pneumoniae (39) (Figure 2B
and C).
Optimizing theART system I—different L-arginine-
dependenttransactivator variants
Weber and colleagues (9) have demonstrated that the type
of transactivation domain fused to the response regulator
may impact overall regulation performance. To character-
ize potential alternatives to the p65 transactivation
domain, we fused the Chlamydia pneumoniae L-arginine-
dependent transactivator to the VP16 domain from
Herpes simplex (ARG2) (53) and the transactivation
domain of the human E2F4 (ARG3) (54) (Figure 3A).
For comparative analysis of the regulation performance,
ARG1-, ARG2- and ARG3-encoding plasmids were co-
transfected with pSH93 (PART1-SEAP-pA) into CHO-K1
and SEAP production was proﬁled after cultivation
for 60h in medium containing either 10mg/l or 1g/l
L-arginine (pSH120 and pSH93: 1.12 0.12U/l (10mg/l
L-arginine), 7.25 0.39U/l (1g/l L-arginine); pSH91
and pSH93: 0.50 0.07 U/l (10mg/l L-arginine),
10.66 0.09U/l (1g/l L-arginine); pSH121 and pSH93:
0.75 0.22U/l (10mg/l L-arginine), 2.76 0.08 U/l (1g/l
L-arginine). SEAP expression values of the diﬀerent
transactivator–promoter combinations exhibited varied
performance characteristics with the basal expression of
ARG2 being slightly lower compared to ARG1 and
ARG3 exhibiting the poorest performance characterized
by lower maximum and higher basal expression levels.
Taken together, co-transfection of PART1 with ARG2
enabled the highest induction performance for SEAP
expression (Figure 3B–D, SEAP values with PART1).
Optimizing theART system II—promoter variants which
differ in thedistance between ARG box operatorand
minimal promoter
The relative spacing of promoter components such as
operator and minimal promoter inﬂuences the assembly of
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maximum transcription levels (55,56). We have, therefore,
engineered PART1 variants containing an increasing
number of 2bp insertions between OARG and PhCMVmin
which modiﬁes the distance and the torsion angle between
these promoter components. While PART1 harbors the
default 21bp between the putative ARG box (OARG)
and PhCMVmin,P ART2 (OARG-2bp-PhCMVmin), PART3
(OARG-4bp-PhCMVmin), PART4 (OARG-6bp-PhCMVmin),
PART5 (OARG-8bp-PhCMVmin) and PART6 (OARG-10bp-
PhCMVmin) contain additional 2, 4, 6, 8 and 10bp between
OARG and PhCMVmin. All promoters were cloned 5’ of
SEAP resulting in a genetic conﬁguration which were
isogenic to pSH93 (see Table 1). 60h after co-transfection
of pSH120 (PSV40-ARG1-pA), pSH121 (PSV40-ARG3-pA)
or pSH91 (PSV40-ARG2-pA) and either pSH93 or one of
its isogenic derivatives into CHO-K1 and cultivation in
the presence of 10mg/l or 1g/l, SEAP production was
quantiﬁed. When co-transfected with pSH120 or pSH91,
PART2 drove maximum SEAP production while basal
expression was minimal for PART6. Comparing PART2
through PART6, maximum SEAP expression levels seem to
decrease with increasing distance of OARG and PhCMVmin
(Figure 3B and D). For co-transfection of CHO-K1 with
pSH121, E2F4 transactivation domain mediated the
poorest regulation performance, characterized by higher
leakiness (10mg/l L-arginine) and lower maximum expres-
sion levels (1g/l L-arginine) (Figure 3C). Overall, PART1
showed an optimal balance between basal and maximum
expression.
Optimizing the ART system III—promoter variants which
differ inthe numberof ARG box operator modules
Increasing the number of tandem operator modules
within a trigger-inducible promoter may increase max-
imum expression levels as more transactivators can be
recruited to the promoter (57). The transcriptional
activity of the promoters harboring the operator in a
monomeric (pSH117, PARTm1-SEAP-pA; PARTm1, AscI-
OARG-MluI-0bp-PhCMVmin), dimeric (pSH119, PARTm2-
SEAP-pA; PARTm2, AscI-OARG-7bp-OARG–MluI-0bp-
PhCMVmin), trimeric (pSH126, PARTm3-SEAP-pA;
PARTm3, AscI-OARG-7bp-OARG-7bp-OARG–MluI-0bp-
PhCMVmin) or tetrameric (pSH127, PARTm4-SEAP-pA;
PARTm4, AscI-OARG-7bp-OARG-7bp-OARG–7bp-OARG-
MluI-0bp-PhCMVmin) conﬁguration were assessed in
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Figure 2. Diagram of the ART regulation system. (A) The bacterial
repressor ArgR of Chlamydia pneumoniae, fused to the human NF-kB
transactivation domain (ARG1, ArgR-p65), is expressed in a constitu-
tive manner under the control of the simian virus 40 promoter (PSV40).
The L-arginine-responsive promoter (PART1) harbors an ArgR-speciﬁc
operator sequence (OARG, capital letters, ARG boxes underlined)
upstream of the minimal version of the cytomegalovirus immediate
early promoter (PhCMVmin) and drives expression of a reporter gene
(e.g. human secreted alkaline phosphatase, SEAP) in a L-arginine-
induced manner. All expression units are terminated by a
polyadenylation site (pA). Selected restriction sites are indicated:
A, AatII; B, BssHII; Ba, BamHI; E, EcoRI; H, HindIII; N, NotI;
S, SbfI; X, XbaI, Xh, XhoI. (B) At a low L-arginine concentration
(10mg/l), the ARG1 is in a low-aﬃnity DNA binding state and does
not interact with its speciﬁc operator sequence (OARG); therefore,
expression of the transgene remains silent. At a higher L-arginine
concentration (1g/l), the chimeric transactivator switches to a high-
aﬃnity conformation and activates transcription from PhCMVmin upon
binding to PART1 through direct ARG1-OARG interaction, thus
enabling the transcription of the reporter gene (e.g. SEAP).
(C) CHO-K1 were transiently transfected with pSH120 (PSV40-ARG1-
pA) and pSH93 (PART1-SEAP-pA) and cultivated for 60h in medium
adjusted to L-arginine concentration ranging from 10 to 1000mg/l
before SEAP production was proﬁled. The induction factor of SEAP
expression is indicated on the top of each bar.
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ARG2-pA). In general, increasing the number of operator
modules resulted in higher maximum expression levels but
also higher basal expression (Figure 4A). Having deﬁned
the parameters for optimal transgene regulation, the ART
system was further validated for expression of the multiple
sclerosis therapeutic interferon-b. Interferon-b was cloned
downstream of PART1 (pSH113, PART1-INF-b-pA), which
was transactivated by ARG2 (pSH91, PSV40-ARG2-pA).
CHO-K1 transiently co-transfected with pSH113 and
pSH91 enabled adjustable INF-b expression, when
exposed to L-arginine concentrations ranging from
10mg/l to 1g/l (Figure 4B).
Validation ofthe ARG2—PART1configuration in different
cell lines
Since the combination of ART2 and PART1 provided the
best combination of low leaky and maximum expression
levels, we sought to further validate this system.
Immortalized cell lines of human, rodent and monkey
origin were co-transfected with pSH91 and pSH93. Sixty
hours post transfection, cells exposed to 10mg/l L-arginine
displayed low SEAP expression, whereas 1g/l L-arginine
induced high-level production of the reporter gene
(Table 2). Moreover, expression integrity of ARG2 in
mammalian cells was conﬁrmed by western blot analysis
using HEK293-T transiently transfected with pSH91
(PSV40-ARG2-pA) (Figure 5).
Autoregulated L-arginine-inducible transgeneexpression
inCHO-K1
The ART system was also validated in an autoregulated
positive feedback conﬁguration enabling one-step installa-
tion of regulated transgene expression in mammalian cells
using a single-vector format. This conﬁguration mediates
simultaneous expression of transactivator and transgene,
both driven by the transactivator-dependent promoter and
was found to be instrumental for the design of noise
resistant gene networks (58). Leaky transcripts mediated
by the PART1 promoter initiate production of relatively
few transactivator molecules which trigger full expression
of PART1-driven transgenes in the presence of L-arginine.
SEAP expression was assessed in CHO-K1 transiently
transfected with pSH122 (pSH122, PART1-SEAP-IRESPV-
ARG2-pA, Figure 6A). PART1 transcription mediates
basal SEAP and ARG2 production which results in
ARG2-triggered auto-induction of the dicistronic expres-
sion unit in the presence of high L-arginine concentrations
(Figure 6B).
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Figure 3. Regulation performance of PART1 variants with diﬀerent
L-arginine-dependent transactivators. (A) Schematic representation of
the diﬀerent L-arginine-dependent transactivators. The bacterial repres-
sor ArgR of Chlamydia pneumoniae, fused to human E2F4 (ARG3,
ArgR-E2F4) or H. simplex VP16 (ARG2, ArgR-VP16). The expression
of both transactivators is driven by the simian virus 40 promoter
(PSV40). Selected restriction sites are indicated: B, BssHII; Ba,
BamHI; E, EcoRI; H, HindIII; N, NotI; Sa, SalI; X, XbaI. The
L-arginine-responsive promoters harboring 0 (PART1), 2 (PART2),
4( P ART3), 6 (PART4), 8 (PART5) and 10 (PART6) bp linkers between
the operator sequence and the minimal promoter were co-transfected
with L-arginine-dependent transactivators containing the (B) human
NF-kB (ARG1, ArgR-p65), (C) human E2F4 (ARG3, ArgR-E2F4)
and (D) H. simplex VP16 (ARG2, ArgR-VP16) transactivation
domains. Cells were grown at low (10mg/l) or high (1g/l) L-arginine
concentrations and SEAP production was assessed 60h after transfec-
tion. The regulation factor for each promoter/transactivator combina-
tion is speciﬁed.
PAGE 7 OF 13 Nucleic Acids Research, 2007, Vol. 35,No. 20 e136Table 2. Quantitative SEAP expression proﬁles under the control of
PART1 in immortalized cell lines with pSH91, an ARG2 encoding vector
and pSH93, a PART1-driven SEAP expression cassette, SEAP expression
levels were determined in cell culture media (U/l), 60h after co-
transfection
Cell line SEAP activity (U/l)
10mg/l L-arginine 1g/l L-arginine
CHO-K1 0.69 0.45 8.08 0.80
HEK-293T 1.67 0.25 21.83 3.19
NIH/3T3 (0.72 0.39) 10
 3 (25.05 2.00) 10
 3
COS-7 0.15 0.07 2.47 0.20
HT-1080 0.04 0.00 0.72 0.06
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Figure 4. (A) Validation of PART1 variants containing a diﬀerent
number of ARG-speciﬁc operator modules. SEAP expression vector
encoding L-arginine-responsive promoters harboring monomeric
(pSH117, PARTm1-SEAP-pA; PARTm1, AscI-OARG-MluI-0bp-
PhCMVmin), dimeric (pSH119, PARTm2-SEAP-pA; PARTm2, AscI-OARG-
7bp-OARG–MluI-0bp-PhCMVmin), trimeric (pSH126, PARTm3-SEAP-pA;
PARTm3, AscI-OARG-7bp-OARG-7bp-OARG–MluI-0bp-PhCMVmin) or tet-
rameric (pSH127, PARTm4-SEAP-pA; PARTm4, AscI-OARG-7bp-OARG-
7bp-OARG–7bp-OARG-MluI-0bp-PhCMVmin) operator modules were
co-transfected with pSH91 (PSV40-ARG2-pA) into CHO-K1 and
SEAP production was proﬁled after 60h. The induction factor is
shown on the top of each bar. (B) Dose–response proﬁle of interferon-b
expression in CHO-K1. Cells were transiently co-transfected with
pSH113 (pSH113, PART1-INF-b-pA) and pSH91 (PSV40-ARG2-pA) and
grown for 48h at diﬀerent L-arginine concentrations before quantiﬁca-
tion of the interferon-b production in the supernatant. Fold induction
is shown on the top of each bar.
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Figure 6. (A) Diagram of the autoregulated L-arginine-inducible SEAP
expression vector (pSH122). pSH122 harbors the L-arginine-responsive
promoter (PART1) which drives transcription of the dicistronic
expression unit encoding the the human placental alkaline phosphatase
(SEAP) in the ﬁrst and the L-arginine-dependent transactivator (ARG2)
in the second cistron. Whereas translation of SEAP occurs via a classic
cap-dependent mechanism, translation-initation of ARG2 is mediated
by an internal ribosome entry site of polioviral origin (IRESPV). pA is
the polyadenylation signal. Selected restriction sites are indicated:
A, AatII; E, EcoRI; N, NotI; X, XbaI, Xh, XhoI. (B) pSH122 was
transiently transfected into CHO-K1, cultivated in media containing
10mg/l or 1g/l L-arginine prior to SEAP quantiﬁcation. Fold induction
is indicated on the top of the bars.
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2
Figure 5. Western blot analysis of ARG2 expression in HEK-293T cells
transfected with pSH91 (pSH91, PSV40-ARG2-pA) and cultivated for
60h. Lane 1, lysate from HEK-293T transfected with pSH91 (pSH91,
PSV40-ARG2-pA); lane 2, lysate from untransfected control cells. The
35kDa band, indicative for the fusion protein ARG2 is shown with a
black arrow. The loading control (tubulin-a, 57kDa) is indicated with
an open arrow. Migration of molecular mass markers (kDa) is
indicated on the left.
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secondary products
In order to assess the speciﬁcity of ART-controlled
transgene expression, we cultivated CHO-K1,
co-transfected with pSH91 (PSV40-ARG2-pA) and
pSH93 (PART1-SEAP-pA), in the presence of increasing
concentrations of L-arginine and several of its derivatives
(L-canavanine, L-homoarginine, L-arginine methyl ester
and L-arginine ethyl ester) and secondary metabolic
products (L-ornithine, L-citrulline, agmatine) and proﬁled
SEAP production after 60h (Figure 7A). Of all these
compounds only L-arginine and its methyl and ethyl esters
induced SEAP to signiﬁcant levels while retaining typical
dose–response characteristics (Figure 7B).
Adjustability and reversibility ofthe ART-controlled
transgeneexpression
In order to determine the adjustability and reversibility of
L-arginine-controlled transgene expression, we generated
a stable CHO-K1-derived cell line transgenic for consti-
tutive ARG2 expression and PART1-controlled SEAP
production (CHO-ARG2-SEAP). CHO-ARG2-SEAP
was cultivated for 60h in medium containing increasing
concentrations of L-argininine before SEAP was proﬁled
in the culture supernatant. As shown in Figure 8A, SEAP
expression could be precisely adjusted to speciﬁc levels
which correlate with particular L-arginine doses. Besides
adjustability, rapid response kinetics and reversibility are
key assets for a mammalian transgene control system.
In order to assess the expression kinetics of the ART
system, we proﬁled both SEAP expression and cell
growth for over 96h. CHO-ARG2-SEAP cells cultivated
in medium supplemented with either 10mg/l or 1g/l
L-arginine displayed similar growth rates, whereby
signiﬁcant SEAP expression was detected only in
CHO-ARG2-SEAP cultivated in the presence of 1g/l
L-arginine (Figure 8B). The reversibility was determined
by cultivating CHO-ARG2-SEAP for up to 1 week while
alternating the inducing (1g/l) or repressing (10mg/l)
culture condition every other day. The SEAP production
proﬁles revealed reproducible sequential expression
kinetics, precise reversibility and tight repression after
ON-to-OFF switching (Figure 8C).
L-arginine-inducible transgeneexpression in mice
For validation of ART-controlled transgene expression
in vivo, we have encapsulated CHO-ARG2-SEAP into
coherent alginate-poly-(L-lysine)-alginate microcapsules
(200 cells per capsule) and implanted them (10
4 capsules
per mouse) intraperitoneally into mice. Implanted mice
were given a daily dose of L-arginine ranging from 0 to
100mg/kg for 72h before quantifying serum SEAP levels.
The SEAP levels reached in the serum of treated mice was
adjustable and dependent on the injected L-arginine dose.
The serum SEAP levels of control mice implanted with
microencapsulated CHO-K1 (data not shown) or mice
implanted with microencapsulated CHO-ARG2-SEAP
but not receiving exogenous L-arginine showed insignif-
icant SEAP expression level (Figure 9A). In parallel,
the experiment was also performed in vitro with the
same batch of encapsulated cells, which conﬁrmed
the dose–response characteristics of microencapsulated
CHO-ARG2-SEAP (Figure 9B).
DISCUSSION
Currently available transgene control systems have been
designed for optimal regulation performance in vitro or in
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Figure 7. Impact of L-arginine and its derivatives on ART-controlled
gene expression. (A) The structure of the L-arginine derivatives
used in this study. (B) Sixty hours after co-transfection with pSH91
(PSV40-ARG2-pA) and pSH93 (PART1-SEAP-pA), SEAP expression of
CHO-K1 was measured. Cells were incubated in cell culture media
containing 10mg/l L-arginine and supplemented with 57.4, 574
or 5740mMo fL-arginine, L-ornithine, L-citrulline, agmatine,
L-homoarginine, L-arginine methyl ester, L-arginine ethyl ester or
L-canavanine (5740mM correspond to 1g/l L-arginine).
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operation within a complex biochemical reaction network
of the host cell, heterologous or modiﬁed endogenous
transcription factors have been engineered to modulate
transcription of speciﬁc target promoters (60,61). Initially,
inducer molecules only required reasonable pharmacoki-
netics and needed to be non-toxic at regulation-eﬀective
concentrations, criteria which was best met by clinically
licensed small-molecule drugs (16,18,62). However, the
use of clinically licensed substances to control biophar-
maceutical manufacturing of diﬃcult-to-produce protein
pharmaceuticals fails to comply with administrative
regulations or requires prohibitive downstream processing
standards (33,63,64). Also, long-term administration of
drugs at (sub-)clinical doses has been associated in many
cases with side-eﬀects which limits their use in future gene
therapy trials (26,28–30). In contrast, physiologic mole-
cules such as amino acids are FDA-licensed media
components and an integral part of host metabolism.
Due to possible interference eﬀects, such physiologic
trigger molecules have so far not been considered for
transgene control.
As an obligate intracellular pathogen, Chlamydia
pneumoniae has evolved to optimally plug in its metabo-
lism into the biochemical networks of host cells (38).
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Figure 8. Dose-dependent control of gene expression and reversibility.
(A) CHO-ARG2-SEAP cells, transgenic for L-arginine-controlled SEAP
expression, were cultured for 60h at diﬀerent L-arginine concentrations
before SEAP expression proﬁling. (B) Growth (line) and production
(bars) kinetics of ART-controlled SEAP production were scored for
CHO-ARG2-SEAP for 96h. (C) Reversibility of L-arginine-mediated
transgene expression following periodic addition and removal of
L-arginine. CHO-ARG2-SEAP cells (110000 cells/ml) were cultivated
in 10mg/l (dotted line) or in 1g/l (solid line) L-arginine at time 0. Every
48h (vertical arrows), cells were readjusted to 110000 cells/ml and
grown in fresh media with reversed L-arginine concentrations.
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Figure 9. ART-inducible SEAP expression in mice. (A) CHO-ARG2-
SEAP cells were microencapsulated in alginate-poly-(L-lysine)-alginate
beads and implanted intraperitoneally into female OF1 mice (2 10
6
cells per mouse). Implanted mice were exposed daily to diﬀerent
arginine concentrations. 72h post-implantation, the level of SEAP in
the serum of mice serum was determined. (B) SEAP expression
of microencapsulated CHO-ARG2-SEAP cells cultured in vitro.
CHO-ARG2-SEAP microencapsulated cells, originating from the
same batch as for the transplantation in mice, were cultured for 72h
at the indicated L-arginine concentration before quantifying SEAP
expression.
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ArgR quantiﬁes L-arginine levels and manages import of
this amino acid (40). It is, therefore, reasonable to assume
that the sensitivity of ArgR is attuned to physiologic
L-arginine levels of mammalian cells. Indeed, ART-con-
trolled expression of reporter and product genes shows
excellent regulation performance (rapid induction kinetics,
full adjustability, reproducible reversibility) in diﬀerent cell
lines as well as in mice with an arginine concentration
window between 10mg/l (required to maintain metabolism,
transgene repressed) and 1g/l (full induction). The
L-arginine level in the plasma of mice is around 17mg/l,
which is well below the threshold concentration required to
fully activate the ART system (52). By default, ART is an
ON-type system, which means that it is only induced in the
presence of increased L-arginine levels and remains
repressed at physiologic concentrations of this amino acid.
ART is exclusively regulated by L-arginine and its ester
forms which are rapidly converted to L-arginine by
endogenous esterases (65). Secondary products of the
L-arginine metabolism or the synthetic L-homoarginine
failed to regulate the ART system. Even L-canavanine,
which is stereochemically similar to L-arginine and was
shown to ﬁt in the amino acid binding pocket of ArgR was
unable to modulate ART-controlled transgene
expression (66).
Since L-arginine is a licensed component of cell culture
media, the ART system will be a extremely valuable
tool for the biomanufacturing of therapeutic proteins.
Moreover, L-arginine is considered to be compatible with
prolonged therapeutic use. In fact, L-arginine is currently
therapeutically administered for pulmonary hypertension
of newborns (67). It also improves endothelial function
in animal models of hypercholesterolaemia and athero-
sclerosis with no life-threatening side-eﬀects reported so
far (68).
As a prototype transgene control system responsive to a
physiologic trigger molecule, the ART system has shown
that metabolic and synthetic control circuits can function-
ally co-exist while sharing the same inducer. Although
such systems may be of immediate use in gene-function
analysis, gene network design as well as for biopharma-
ceutical manufacturing, the ART may develop its highest
impact in future therapies: synchronization of therapeutic
gene expression with ﬂuctuations of endogenous mole-
cules or the self-suﬃcient treatment of a pathological
situation by exploiting signal molecules for a self-
controlling genetic intervention are highly appealing
strategies for future gene therapy applications.
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